1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

20 Sep 2024
Admin
News Article

MHRA Launches New Strategy for Improving Safety Communications on World Patient Safety Day

UK MHRA launches new strategy for improving safety communications on World Patient Safety Day: Improving information to patients and healthcare professionals

Overview

On World Patient Safety Day, 17th September, 2024, the UK Medicines and Healthcare products Regulatory Agency (MHRA) launches a new three-year Strategy for Improving Safety Communications, which aims to transform the way we provide information about the risks and safety of medicines, medical devices and healthcare products in the UK to support effective implementation of new safety measures.

Importance of Effective Communication

Effective communication is essential so that patients are informed of and understand the benefits and risks of medicines and devices they are using, to assist healthcare professionals in best protecting their patients, and to maintain confidence in medical products, the broader health system, and the MHRA.

Latest Safety Information

Healthcare professionals need the latest safety information to advise and support their patients, and we have listened to their feedback in bringing improvements to our communications and systems.
Our strategy is underpinned by the findings of our recent consultation with healthcare professionals and healthcare organisations.
The three-year strategy will deliver to patients and healthcare professionals more co-ordinated, targeted, and impactful safety communications, when they need it, using the best possible communication channels.

About This New Strategy

The new strategy aims to build on the MHRA’s transformed approach to safety following the 2020 Independent Medicines and Medical

Devices Safety Review.

This called for strengthening the MHRA’s processes for monitoring the safety of medicines and medical devices and better working with other bodies to support changes being embedded without delay in clinical practice.

From the MHRA

Dr Alison Cave, Chief Safety Officer at the MHRA, said: “Our new Strategy for Improving Safety Communications will help us ensure patients are better informed about the benefits and risks of medical products.
“We continue to listen to and shape our work in the light of feedback from patients, the public, healthcare professionals and external experts to ensure that we continue to support all those with whom we work to improve patient safety.”

Launching New MHRA Safety Bulletin

In the consultation, healthcare professionals raised their workload and time pressures, and the volume of safety warnings they receive.
We will therefore launch a new MHRA Safety ‘round up’ bulletin to bring together safety advice communicated by the MHRA each month across all the medical products we regulate.
We will also continue to issue safety communications throughout the month in a targeted way, to anyone who wishes to receive them.
Healthcare professionals who took part in the consultation asked for more information about the MHRA’s safety warnings and how they should be actioned.
We will launch campaigns to raise awareness of the role of the MHRA and the importance of our safety communications.

Many organisations asked the MHRA to have better avenues for feedback on new safety warnings. We will build closer relationships with healthcare organisations and with healthcare professionals, to ensure our advice is actionable and informed by their needs.

Work to Increase Patient Reach

The MHRA will also continue to build and increase its direct reach to patients, including through use of innovative mechanisms and communication methods that are tailored to their needs.
To inform our approaches, there will be a further consultation with patients and patient representatives next year.

About MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.
All its work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
The MHRA is an executive agency of the Department of Health and Social Care.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!